According to Stéphane Bancel, Chief Executive Officer of Moderna in January 2022 “EBV is one of the most common viral infections in the world, despite the fact that it causes infectious mononucleosis, which impacts millions of adolescents globally, no vaccine is currently available.” The Moderna CEO called the start of a Phase 1 study for an mRNA vaccine to be a “significant milestone” as they continued to “to advance mRNA vaccines against latent viruses,” the European Pharmaceutical Review reported. That early stage clinical trial for Epstein Barr virus has now been halted due to a suspected case of Myocarditis and there is an immediate suspension of all dosing for all adolescents, according to Alex Berenson in an Exclusive report, on the 17th November which is republished below.
